Patent intelligence · US
US 6593394
Bioactive and osteoporotic bone cement
Bioactive and osteoporotic bone cement
Patent details — US 6593394
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 15, 2003
- Expiration
- Jul 10, 2023
- Applicant
- Prosperous Kingdom Limited
- Claims
- 10
- CPC classes
- A61K, A61K6/838, A61K6/887
Quick answer
US 6593394 (Bioactive and osteoporotic bone cement) is held by Prosperous Kingdom Limited. Status: expired. Granted Jul 15, 2003. Expires Jul 10, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Prosperous Kingdom Limited
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K6/838, A61K6/887
More from Prosperous Kingdom Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428395
Heterocyclic compounds as kinase inhibitor and uses thereof
granted -
US 12291548
Compounds, compositions, and methods for the treatment of disease
granted -
US 12226403
Tebipenem pivoxil immediate and modified release oral dosage forms
granted -
US 12146004
Polymyxin compounds and uses thereof
granted -
US 12098155
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 12048691
High dosage tebipenem pivoxil tablet formulation
granted -
US 11718621
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 11459357
Polymyxin compounds
granted
Frequently asked questions
What is US patent 6593394?
US 6593394 (Bioactive and osteoporotic bone cement) is held by Prosperous Kingdom Limited. Status: expired. Granted Jul 15, 2003. Expires Jul 10, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6593394?
Prosperous Kingdom Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 6593394 expire?
Our index shows an expiration date of Jul 10, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.